Viatris Inc. or Xenon Pharmaceuticals Inc.: Who Invests More in Innovation?

Viatris vs. Xenon: A Decade of R&D Investment

__timestampViatris Inc.Xenon Pharmaceuticals Inc.
Wednesday, January 1, 201458180000011768000
Thursday, January 1, 201567190000015152000
Friday, January 1, 201687670000019828000
Sunday, January 1, 201785790000025573000
Monday, January 1, 201882220000023634000
Tuesday, January 1, 201977820000038845000
Wednesday, January 1, 202051260000050523000
Friday, January 1, 202168100000075463000
Saturday, January 1, 2022662200000105767000
Sunday, January 1, 2023910700000167512000
Loading chart...

In pursuit of knowledge

Innovation Investment: A Tale of Two Companies

In the ever-evolving pharmaceutical industry, innovation is the lifeblood of progress. Viatris Inc. and Xenon Pharmaceuticals Inc. are two companies that exemplify this drive. Over the past decade, Viatris has consistently outpaced Xenon in research and development (R&D) spending, investing nearly 14 times more on average. In 2023, Viatris allocated approximately 91% of its R&D budget compared to Xenon's 9%, highlighting a significant commitment to innovation. However, Xenon has shown remarkable growth, increasing its R&D expenses by over 1,300% since 2014. This surge reflects Xenon's strategic focus on pioneering treatments. As the pharmaceutical landscape continues to shift, these investments underscore the critical role of R&D in shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025